Research
Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States
-
* Corresponding author: Haya Ascher-Svanum haya@lilly.com
Cost Effectiveness and Resource Allocation 2009, 7:4 doi:10.1186/1478-7547-7-4
No comments have yet been made on this article.